IAI FigSearch
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Xie, H.
Right arrow Articles by Klinman, D. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Xie, H.
Right arrow Articles by Klinman, D. M.

 Previous Article  |  Next Article 

Infection and Immunity, February 2005, p. 828-833, Vol. 73, No. 2
0019-9567/05/$08.00+0     doi:10.1128/IAI.73.2.828-833.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

CpG Oligodeoxynucleotides Adsorbed onto Polylactide-Co-Glycolide Microparticles Improve the Immunogenicity and Protective Activity of the Licensed Anthrax Vaccine

Hang Xie,1 Ihsan Gursel,1 Bruce E. Ivins,2 Manmohan Singh,3 Derek T. O'Hagan,3 Jeffrey B. Ulmer,3 and Dennis M. Klinman1*

Section of Retroviral Immunology, Center for Biologics Evaluation Research, Food and Drug Administration, Bethesda,1 Bacteriology Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland,2 Chiron Vaccines, Emeryville, California3

Received 9 August 2004/ Returned for modification 14 September 2004/ Accepted 3 October 2004

To reduce the biothreat posed by anthrax, efforts are under way to improve the protection afforded by vaccination. This work examines the ability of immunostimulatory CpG oligodeoxynucleotides (ODN) adsorbed onto cationic polylactide-co-glycolide (PLG) microparticles (CpG ODN-PLG) to accelerate and boost the protective immunity elicited by Anthrax Vaccine Adsorbed (AVA, the licensed human anthrax vaccine). The results indicate that coadministering CpG ODN-PLG with AVA induces a stronger and faster immunoglobulin G response against the protective antigen of anthrax than AVA alone. Immunized mice were protected from lethal anthrax challenge within 1 week of vaccination with CpG ODN-PLG plus AVA, with the level of protection correlating with serum immunoglobulin G anti-protective antigen titers.

* Corresponding author. Mailing address: Center for Biologics Evaluation Research, Food and Drug Administration, Bldg. 29A, Rm. 3D10, Bethesda, MD 20892. Phone: (301) 827-1707. Fax: (301) 496-1810. E-mail: Klinman{at}cber.fda.gov.

Editor: J. D. Clements

Infection and Immunity, February 2005, p. 828-833, Vol. 73, No. 2
0019-9567/05/$08.00+0     doi:10.1128/IAI.73.2.828-833.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
J. Bacteriol. J. Virol. Eukaryot. Cell
Microbiol. Mol. Biol. Rev. Clin. Vaccine Immunol. All ASM Journals

Copyright © 2005 by the American Society for Microbiology. All rights reserved.